Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics, Inc. (ACRV) Chief Legal Officer Mary Miller reported the sale of 294 shares of common stock on October 5, 2026, at a weighted average price of $1.99 per share. The shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units. Miller directly held 81,715 shares following the transaction.
Acrivon Therapeutics, Inc. (ACRV) reported that Chief Business Officer Michaela Levin received equity-based compensation on August 31, 2026. She was granted 130,000 options to buy common stock at an exercise price of $2.09 per share, expiring August 30, 2036, and 30,000 restricted stock units
Acrivon Therapeutics, Inc. (ACRV) filed an initial statement of beneficial ownership on Form 3 for Michaela LevinChief Business Officer. The filing reports no transactions, no derivative positions and no shareholdings, and includes an exhibit listing a Power of Attorney authorizing Form 3-related actions.
Acrivon Therapeutics, Inc. (ACRV) reported that President and CEO Dr. Peter Blume-Jensen, who is also a director, and co-founder and EVP Business Operations Dr. Kristina Masson, also a director, filed a joint Form 4. On 2026-08-25, 14,036 shares of Common Stock were sold at a weighted average price of $2.2064 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. Following this transaction, Dr. Blume-Jensen held 2,230,052 shares directly, and there were 385,859 shares held indirectly through securities held by Dr. Masson. Each spouse disclaims beneficial ownership of the other’s reported holdings except to the extent of their pecuniary interest.
Acrivon Therapeutics, Inc. (ACRV) received a notice under Rule 144 relating to potential sales of its common stock by President and CEO Dr. Peter Blume-Jensen. The notice lists 41,167 shares of common stock to be sold upon settlement on 08/21/2026, arising from vested RSUs issued under an S-8 equity compensation plan, with the issuer shown as the source and the purpose described as equity compensation for services rendered.
The filing also reports that in the prior three months, automatic sales were made solely to cover mandatory tax withholding on RSU vesting: on 08/18/2026, Dr. Blume-Jensen sold 1,229 shares for proceeds of $2,470.29, and his spouse, director and officer Dr. Kristina Masson, sold 484 shares for proceeds of $972.84. The shares to be sold are held through Morgan Stanley Smith Barney LLC Executive Services, with a listed market on NASDAQ.
Acrivon Therapeutics, Inc. (ACRV) reported that Chief Accounting Officer Katharine Peterson sold 101 shares of common stock on 2026-08-18 at $2.01 per share. According to the company’s disclosure, these shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and she now holds 18,033 shares directly.
Acrivon Therapeutics, Inc. (ACRV) reported an insider transaction by Chief Legal Officer Mary Miller. On 2026-08-18, she sold 185 shares of common stock at $2.01 per share. The shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and she now holds 82,009 shares directly.
Acrivon Therapeutics, Inc. (ACRV) reported that Chief Development Officer Erick Gamelin had 400 shares of common stock sold on August 18, 2026 at $2.01 per share. According to the disclosure, these shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, leaving him with 52,592 shares held directly.
Acrivon Therapeutics, Inc. (ACRV) reported that Chief Operating Officer Eric Devroe had 604 shares of common stock sold on 2026-08-18 at $2.01 per share. According to the company, the shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and Devroe now holds 146,349 shares directly.
Acrivon Therapeutics, Inc. (ACRV) reported insider transactions involving President and CEO Dr. Peter Blume-Jensen and EVP Dr. Kristina Masson. On 2026-08-18, a total of 1,713 shares of Common Stock were sold at $2.01 per share to satisfy a mandatory tax withholding requirement upon vesting of restricted stock units.
Of these, 1,229 shares were sold from shares held by Dr. Blume-Jensen, leaving 2,244,088 shares held directly. Another 484 shares were sold from shares held by Dr. Masson, leaving 385,859 shares held indirectly, with each spouse disclaiming beneficial ownership of the other’s securities except for their pecuniary interest.